Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

PD-L1 blockade enhances anti-tumor efficacy of NK cells.

Oyer JL, Gitto SB, Altomare DA, Copik AJ.

Oncoimmunology. 2018 Aug 27;7(11):e1509819. doi: 10.1080/2162402X.2018.1509819. eCollection 2018.

2.

Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer.

Gitto SB, Pandey V, Oyer JL, Copik AJ, Hogan FC, Phanstiel O 4th, Altomare DA.

Mol Pharm. 2018 Feb 5;15(2):369-376. doi: 10.1021/acs.molpharmaceut.7b00718. Epub 2018 Jan 4.

PMID:
29299930
3.

Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches.

Kamta J, Chaar M, Ande A, Altomare DA, Ait-Oudhia S.

Front Oncol. 2017 Apr 18;7:64. doi: 10.3389/fonc.2017.00064. eCollection 2017. Review.

4.

Development and validation of a LC-MS/MS assay for quantification of cisplatin in rat plasma and urine.

Shaik AN, Altomare DA, Lesko LJ, Trame MN.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Mar 1;1046:243-249. doi: 10.1016/j.jchromb.2016.11.027. Epub 2016 Nov 23.

PMID:
28162967
5.

ATP13A3 and caveolin-1 as potential biomarkers for difluoromethylornithine-based therapies in pancreatic cancers.

Madan M, Patel A, Skruber K, Geerts D, Altomare DA, Iv OP.

Am J Cancer Res. 2016 Jun 1;6(6):1231-52. eCollection 2016.

6.

Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment.

Oyer JL, Pandey V, Igarashi RY, Somanchi SS, Zakari A, Solh M, Lee DA, Altomare DA, Copik AJ.

Cytotherapy. 2016 May;18(5):653-63. doi: 10.1016/j.jcyt.2016.02.006.

PMID:
27059202
7.

Anti-ovarian tumor response of donor peripheral blood mononuclear cells is due to infiltrating cytotoxic NK cells.

Pandey V, Oyer JL, Igarashi RY, Gitto SB, Copik AJ, Altomare DA.

Oncotarget. 2016 Feb 9;7(6):7318-28. doi: 10.18632/oncotarget.6939.

8.

Prediabetes linked to excess glucagon in transgenic mice with pancreatic active AKT1.

Albury-Warren TM, Pandey V, Spinel LP, Masternak MM, Altomare DA.

J Endocrinol. 2016 Jan;228(1):49-59. doi: 10.1530/JOE-15-0288. Epub 2015 Oct 20.

9.

Constitutively active Akt1 cooperates with KRas(G12D) to accelerate in vivo pancreatic tumor onset and progression.

Albury TM, Pandey V, Gitto SB, Dominguez L, Spinel LP, Talarchek J, Klein-Szanto AJ, Testa JR, Altomare DA.

Neoplasia. 2015 Feb;17(2):175-82. doi: 10.1016/j.neo.2014.12.006.

10.

Generation of highly cytotoxic natural killer cells for treatment of acute myelogenous leukemia using a feeder-free, particle-based approach.

Oyer JL, Igarashi RY, Kulikowski AR, Colosimo DA, Solh MM, Zakari A, Khaled YA, Altomare DA, Copik AJ.

Biol Blood Marrow Transplant. 2015 Apr;21(4):632-9. doi: 10.1016/j.bbmt.2014.12.037. Epub 2015 Jan 6.

11.

The effect of calorie restriction on insulin signaling in skeletal muscle and adipose tissue of Ames dwarf mice.

Wiesenborn DS, Menon V, Zhi X, Do A, Gesing A, Wang Z, Bartke A, Altomare DA, Masternak MM.

Aging (Albany NY). 2014 Oct;6(10):900-12.

12.

Synthesis and biological evaluation of antimetastatic agents predicated upon dihydromotuporamine C and its carbocyclic derivatives.

Muth A, Pandey V, Kaur N, Wason M, Baker C, Han X, Johnson TR, Altomare DA, Phanstiel O 4th.

J Med Chem. 2014 May 22;57(10):4023-34. doi: 10.1021/jm401906v. Epub 2014 May 2.

PMID:
24784222
13.
14.

Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis.

Altomare DA, Menges CW, Xu J, Pei J, Zhang L, Tadevosyan A, Neumann-Domer E, Liu Z, Carbone M, Chudoba I, Klein-Szanto AJ, Testa JR.

PLoS One. 2011 Apr 19;6(4):e18828. doi: 10.1371/journal.pone.0018828.

15.

Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.

Mabuchi S, Kawase C, Altomare DA, Morishige K, Hayashi M, Sawada K, Ito K, Terai Y, Nishio Y, Klein-Szanto AJ, Burger RA, Ohmichi M, Testa JR, Kimura T.

Mol Cancer Ther. 2010 Aug;9(8):2411-22. doi: 10.1158/1535-7163.MCT-10-0169. Epub 2010 Jul 27.

16.

Onconase responsive genes in human mesothelioma cells: implications for an RNA damaging therapeutic agent.

Altomare DA, Rybak SM, Pei J, Maizel JV, Cheung M, Testa JR, Shogen K.

BMC Cancer. 2010 Feb 5;10:34. doi: 10.1186/1471-2407-10-34.

17.

GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt.

Altomare DA, Zhang L, Deng J, Di Cristofano A, Klein-Szanto AJ, Kumar R, Testa JR.

Clin Cancer Res. 2010 Jan 15;16(2):486-96. doi: 10.1158/1078-0432.CCR-09-1026.

18.

Appl1 is dispensable for mouse development, and loss of Appl1 has growth factor-selective effects on Akt signaling in murine embryonic fibroblasts.

Tan Y, You H, Wu C, Altomare DA, Testa JR.

J Biol Chem. 2010 Feb 26;285(9):6377-89. doi: 10.1074/jbc.M109.068452. Epub 2009 Dec 29.

19.

mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.

Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ, Ohmichi M, Testa JR, Kimura T.

Clin Cancer Res. 2009 Sep 1;15(17):5404-13. doi: 10.1158/1078-0432.CCR-09-0365. Epub 2009 Aug 18.

20.

FAS-associated factor 1 (FAF1): diverse functions and implications for oncogenesis.

Menges CW, Altomare DA, Testa JR.

Cell Cycle. 2009 Aug 15;8(16):2528-34. Epub 2009 Aug 16. Review.

21.

Recurrent chromosomal rearrangements implicate oncogenes contributing to T-cell lymphomagenesis in Lck-MyrAkt2 transgenic mice.

Timakhov RA, Tan Y, Rao M, Liu Z, Altomare DA, Pei J, Wiest DL, Favorova OO, Knepper JE, Testa JR.

Genes Chromosomes Cancer. 2009 Sep;48(9):786-94. doi: 10.1002/gcc.20683.

22.

Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice.

Altomare DA, Menges CW, Pei J, Zhang L, Skele-Stump KL, Carbone M, Kane AB, Testa JR.

Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3420-5. doi: 10.1073/pnas.0808816106. Epub 2009 Feb 17.

23.

A novel recurrent chromosomal inversion implicates the homeobox gene Dlx5 in T-cell lymphomas from Lck-Akt2 transgenic mice.

Tan Y, Timakhov RA, Rao M, Altomare DA, Xu J, Liu Z, Gao Q, Jhanwar SC, Di Cristofano A, Wiest DL, Knepper JE, Testa JR.

Cancer Res. 2008 Mar 1;68(5):1296-302. doi: 10.1158/0008-5472.CAN-07-3218.

24.

HGF mediates cell proliferation of human mesothelioma cells through a PI3K/MEK5/Fra-1 pathway.

Ramos-Nino ME, Blumen SR, Sabo-Attwood T, Pass H, Carbone M, Testa JR, Altomare DA, Mossman BT.

Am J Respir Cell Mol Biol. 2008 Feb;38(2):209-17. Epub 2007 Sep 13.

25.

RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model.

Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF, Testa JR.

Clin Cancer Res. 2007 Jul 15;13(14):4261-70.

26.

Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.

Garland LL, Rankin C, Gandara DR, Rivkin SE, Scott KM, Nagle RB, Klein-Szanto AJ, Testa JR, Altomare DA, Borden EC.

J Clin Oncol. 2007 Jun 10;25(17):2406-13.

PMID:
17557954
27.

RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.

Mabuchi S, Altomare DA, Connolly DC, Klein-Szanto A, Litwin S, Hoelzle MK, Hensley HH, Hamilton TC, Testa JR.

Cancer Res. 2007 Mar 15;67(6):2408-13.

28.

Cellular and molecular parameters of mesothelioma.

Ramos-Nino ME, Testa JR, Altomare DA, Pass HI, Carbone M, Bocchetta M, Mossman BT.

J Cell Biochem. 2006 Jul 1;98(4):723-34. Review.

29.

Perturbations of the AKT signaling pathway in human cancer.

Altomare DA, Testa JR.

Oncogene. 2005 Nov 14;24(50):7455-64. Review.

PMID:
16288292
30.

A mouse model recapitulating molecular features of human mesothelioma.

Altomare DA, Vaslet CA, Skele KL, De Rienzo A, Devarajan K, Jhanwar SC, McClatchey AI, Kane AB, Testa JR.

Cancer Res. 2005 Sep 15;65(18):8090-5.

31.

SV40-dependent AKT activity drives mesothelial cell transformation after asbestos exposure.

Cacciotti P, Barbone D, Porta C, Altomare DA, Testa JR, Mutti L, Gaudino G.

Cancer Res. 2005 Jun 15;65(12):5256-62.

32.

Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth.

Altomare DA, You H, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, Jhanwar SC, Mossman BT, Kane AB, Testa JR.

Oncogene. 2005 Sep 8;24(40):6080-9.

PMID:
15897870
33.

Positive feedback regulation between AKT activation and fatty acid synthase expression in ovarian carcinoma cells.

Wang HQ, Altomare DA, Skele KL, Poulikakos PI, Kuhajda FP, Di Cristofano A, Testa JR.

Oncogene. 2005 May 19;24(22):3574-82.

PMID:
15806173
34.

The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression.

Xiao GH, Gallagher R, Shetler J, Skele K, Altomare DA, Pestell RG, Jhanwar S, Testa JR.

Mol Cell Biol. 2005 Mar;25(6):2384-94.

35.

Loss of methylthioadenosine phosphorylase and elevated ornithine decarboxylase is common in pancreatic cancer.

Subhi AL, Tang B, Balsara BR, Altomare DA, Testa JR, Cooper HS, Hoffman JP, Meropol NJ, Kruger WD.

Clin Cancer Res. 2004 Nov 1;10(21):7290-6.

36.

AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth.

Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, Testa JR.

Oncogene. 2004 Jul 29;23(34):5853-7.

PMID:
15208673
37.

Frequent activation of AKT2 kinase in human pancreatic carcinomas.

Altomare DA, Tanno S, De Rienzo A, Klein-Szanto AJ, Tanno S, Skele KL, Hoffman JP, Testa JR.

J Cell Biochem. 2002;87(4):470-6. Erratum in: J Cell Biochem. 2003 Jan 1;88(1):470.

PMID:
14735903
38.

Mitochondrial and peroxisomal manganese superoxide dismutase: differential expression during leaf senescence.

del Río LA, Sandalio LM, Altomare DA, Zilinskas BA.

J Exp Bot. 2003 Mar;54(384):923-33.

PMID:
12598563
39.

AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survival.

Bacus SS, Altomare DA, Lyass L, Chin DM, Farrell MP, Gurova K, Gudkov A, Testa JR.

Oncogene. 2002 May 16;21(22):3532-40.

40.

AKT activation up-regulates insulin-like growth factor I receptor expression and promotes invasiveness of human pancreatic cancer cells.

Tanno S, Tanno S, Mitsuuchi Y, Altomare DA, Xiao GH, Testa JR.

Cancer Res. 2001 Jan 15;61(2):589-93.

41.

Akt2 mRNA is highly expressed in embryonic brown fat and the AKT2 kinase is activated by insulin.

Altomare DA, Lyons GE, Mitsuuchi Y, Cheng JQ, Testa JR.

Oncogene. 1998 May 7;16(18):2407-11.

42.

Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis.

Cheng JQ, Altomare DA, Klein MA, Lee WC, Kruh GD, Lissy NA, Testa JR.

Oncogene. 1997 Jun 12;14(23):2793-801.

43.

Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA.

Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK, Testa JR.

Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3636-41.

44.

Chromosome mapping of the mouse Akt2 gene and Akt2 pseudogene.

Altomare DA, Kozak CA, Sonoda G, Testa JR.

Cytogenet Cell Genet. 1996;74(4):248-51.

PMID:
8976376
45.

Cloning, chromosomal localization and expression analysis of the mouse Akt2 oncogene.

Altomare DA, Guo K, Cheng JQ, Sonoda G, Walsh K, Testa JR.

Oncogene. 1995 Sep 21;11(6):1055-60.

PMID:
7566964
46.

Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.

Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA, Wan M, Dubeau L, Scambia G, Masciullo V, Ferrandina G, Benedetti Panici P, Mancuso S, Neri G, Testa JR.

Int J Cancer. 1995 Aug 22;64(4):280-5.

PMID:
7657393
47.

Molecular cloning and localization of the human GAX gene to 7p21.

LePage DF, Altomare DA, Testa JR, Walsh K.

Genomics. 1994 Dec;24(3):535-40.

PMID:
7713505
48.

p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma.

Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee WC, Altomare DA, Nobori T, Olopade OI, Buckler AJ, Testa JR.

Cancer Res. 1994 Nov 1;54(21):5547-51.

49.

A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1.

Godwin AK, Vanderveer L, Schultz DC, Lynch HT, Altomare DA, Buetow KH, Daly M, Getts LA, Masny A, Rosenblum N, et al.

Am J Hum Genet. 1994 Oct;55(4):666-77.

Supplemental Content

Loading ...
Support Center